Explore the Potential with AI-Driven Innovation
The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.
We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.
The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.
We utilise our cutting-edge, exclusive workflow to develop focused libraries for receptors.
Fig. 1. The sreening workflow of Receptor.AI
It includes extensive molecular simulations of the receptor in its native membrane environment and the ensemble virtual screening accounting for its conformational mobility. In the case of dimeric or oligomeric receptors, the whole functional complex is modelled, and the tentative binding pockets are determined on and between the subunits to cover the whole spectrum of possible mechanisms of action.
Key features that set our library apart include:
partner
Reaxense
upacc
Q15743
UPID:
OGR1_HUMAN
Alternative names:
G-protein coupled receptor 68; GPR12A; Sphingosylphosphorylcholine receptor
Alternative UPACC:
Q15743; Q13334; Q4VBB4; Q6IX34
Background:
Ovarian cancer G-protein coupled receptor 1 (Q15743), also known as G-protein coupled receptor 68, GPR12A, and Sphingosylphosphorylcholine receptor, plays a crucial role in pH homeostasis. It functions as a proton-sensing receptor, vital for regulating cell-mediated responses to acidosis in bone, and is activated at lower pH levels. This receptor is also implicated in suppressing metastasis in prostate cancer.
Therapeutic significance:
The protein's involvement in Amelogenesis imperfecta, hypomaturation type, 2A6, a disorder affecting enamel formation, highlights its potential as a target for therapeutic intervention. Understanding the role of Ovarian cancer G-protein coupled receptor 1 could open doors to potential therapeutic strategies.